PRTC
PureTech Health plc
NASDAQ · Healthcare · Biotechnology · US
$17.38
+2.12%Year over year
Reported trailing growth
- Revenue
- -53.7%
- EBITDA
- +42.8%
- EBIT
- +32.7%
- EPS
- —
- Free cash flow
- +25.7%
- Operating cash flow
- +25.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +30.6%
- EBITDA
- —
- EBIT
- +27.6%
- Net income
- —
- EPS
- —
- Free cash flow
- +36.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025